Innovent and Lilly to advance new oncology and immunology medicines
Innovent will receive an upfront payment of $350m under the agreement.
Drug Development
Novartis starts construction on new research facility in San Diego, US
BMS reports flat revenue growth for full-year 2025
Apotex and Grünenthal sign deal for Nebido Canadian distribution
Everest Medicines and Micot partner on MT1013 commercialisation
PrimeGen US and DT Cloud Star sign $1.5bn merger agreement
Relay Therapeutics’ zovegalisib secures FDA BTD for advanced breast cancer
CEPI and Samsung Biologics partner to boost global vaccine preparedness
